Nephron Sparing for Renal Cell Carcinoma: Whenever Possible?

Area of Science:

• Nephrology
• Urologic Oncology
• Cardiovascular Medicine

Background:

• Nephron-sparing surgery (NSS) is frequently preferred over radical nephrectomy (RN) for localized renal tumors when a normal contralateral kidney is present.
• Observational studies suggest NSS improves overall, cancer-specific, and cardiovascular survival compared to RN in such cases.
• However, definitive evidence from randomized controlled trials (RCTs) is limited.

Purpose of the Study:

• To compare the long-term oncological and cardiovascular outcomes of nephron-sparing surgery versus radical nephrectomy in patients with a normal contralateral kidney.
• To evaluate the impact of surgical approach on overall survival, cancer-specific survival, and cardiac disease-specific survival.

Main Methods:

• Review of existing literature, including observational studies and the single available randomized clinical trial.
• Analysis of patient data focusing on survival endpoints and renal function.
• Comparison of outcomes between patients undergoing NSS and those undergoing RN.

Main Results:

• Multiple open studies consistently demonstrated superior overall, cancer-specific, and cardiac disease-specific survival with NSS compared to RN.
• The single randomized clinical trial, however, failed to confirm the superiority of NSS over RN in terms of survival benefits.
• Discrepancies between observational data and RCT findings highlight the need for further investigation.

Conclusions:

• While observational data strongly support nephron-sparing surgery for improved survival in patients with a normal contralateral kidney, the definitive randomized trial did not corroborate these findings.
• Further high-quality randomized trials are warranted to definitively establish the superiority of nephron-sparing surgery over radical nephrectomy regarding survival outcomes.
• The optimal surgical management for renal tumors with a normal contralateral kidney remains an area requiring continued research and clinical evaluation.